Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours

Summary: Background: PT-112, the first pyrophosphate-platinum conjugate, causes immunogenic cell death in experimental models, leading to recruitment of tumour-infiltrating lymphocytes. PT-112 also associates with bone (osteotropism), likely driven by its pyrophosphate moiety. This is the first-in-...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Daniel D. Karp, D. Ross Camidge, Jeffery R. Infante, Tyler D. Ames, Matthew R. Price, José Jimeno, Alan H. Bryce
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2022-07-01
Edice:	EClinicalMedicine
Témata:	Phase I clinical trials Small molecule agent Lung cancer Prostate cancer Pharmacokinetics Immunogenic cell death
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589537022001602
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!